Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-conviction stock picks and new investing ...
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease ...
MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Data API Builder helps developers expose database objects through REST and GraphQL without building extensive custom data access code. Steve Jones' Visual Studio Live! San Diego 2026 session will show ...
Google API keys for services like Maps embedded in accessible client-side code could be used to authenticate to the Gemini AI assistant and access private data. Researchers found nearly 3,000 such ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...
Eikon Therapeutics shares were down 6%, at $16.90, in the stock's first day of trade on the Nasdaq Global Select Market. Shares of the clinical-stage biopharmaceutical company began trading midday ...
Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results